Siegfried

Siegfried Opens New Drug Substances R&D Center in Evionnaz

Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried inaugurated its new global research and development (R&D) center for drug substances at its site in Evionnaz, Switzerland. The 4,500 m2 center houses chemical and analytical facilities, laboratories, and technologies such as flow chemistry, advanced distillation and process analytical technology, as well as new office space.

Siegfried to Buy Early-Phase CDMO Site from Curia

Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried has signed a binding agreement to acquire an early-phase CDMO site in Grafton, Wisconsin, US, from Curia. The transaction is expected to close by July 1, subject to customary closing conditions.

Siegfried to Acquire Early-Phase CDMO in US

Siegfried, a global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen, Switzerland, has signed binding agreements with Curia Global for the acquisition of an early-phase CDMO site in Grafton, Wisconsin, US.

Siegfried Announces Changes in Senior Management Team

Siegfried has appointed Marianne Späne, currently chief business officer Drug Products, as chief business officer with responsibility for both the Drug Substances and Drug Products divisions of the Swiss contract manufacturing and development organization (CDMO), effective Feb. 1, 2024. Christian Dowdeswell, who previously led the Drug Substance business, has decided to leave Siegfried.

Expanding Expertise in Highly-Potent APIs

After acquiring the two Catalonian sites in Barberà del Vallès and El Masnou about two years ago, Siegfried is now significantly expanding its expertise in the production of complex Drug Products containing Highly-Potent APIs (HPAPIs). In addition, the company has opened a new development center for oral solid dosage forms with active ingredients and HPAPIs as well as for ophthalmic sterile products. This not only strengthens Siegfried's position in the area of drug products, but also its global network and international competitiveness.

Special Issue: Swiss CDMO Siegfried Celebrates 150th Anniversary

There are only a few chemical and pharmaceutical companies that look back at a history of 150 years. Certainly, many companies claim such a long legacy, but if you only count those that have been operating and thriving under the same name for a century and a half, the number boils down significantly.

Siegfried Demonstrates Biologics Expertise in Hameln

The Fill & Finish of biologic drugs is expensive and poses special technological challenges for CDMOs. At the German site in Hameln, Siegfried has successfully proven these capabilities over the past two years by producing Covid-19 vaccines and a significant number of clinical batches for several biological companies. By investing in its competencies, capacities and flexibility, the company intends to further expand this demanding but promising business area.

"We Want to Be a Big Fish"

The CDMO (contract development and manufacturing organizations) business has a bright future, of that Siegfried CEO Wolfgang Wienand is certain. The economic advantages alone speak for this compared to in-house production by the pharmaceutical companies themselves. Although Siegfried has already reached sufficient critical size within its industry, he sees the company continuing on its growth path. The goal is to take over an even larger share of the value chain from pharmaceutical companies in the future.

The New Globalism

Siegfried Acquires Hameln Pharma

Swiss Visionary

Expect More

Siegfried acquires Alliance Medical Products

Siegfried Reports Higher Operating Results for 2010

Siegfried Outsources Support Functions

Siegfried Announces Capital Increase and Grows In Core Business

Siegfried to Introduce Functional Organization